Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABLYSINOL vs AZATHIOPRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.
Azathioprine is a purine analog that inhibits purine nucleotide synthesis, thereby suppressing DNA replication and cell proliferation. It is converted to 6-mercaptopurine, which acts as a purine antagonist, inhibiting de novo purine synthesis and interfering with RNA and DNA synthesis, particularly in rapidly dividing cells such as T-lymphocytes.
Empiric therapy for presumed fungal infection in febrile neutropenic patients,Treatment of systemic fungal infections (e.g., aspergillosis, candidiasis, cryptococcosis),Treatment of visceral leishmaniasis
Renal transplant rejection prophylaxis (FDA),Rheumatoid arthritis (FDA),Off-label: autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease (Crohn's disease, ulcerative colitis), pemphigus, myasthenia gravis, dermatomyositis/polymyositis,Off-label: myelodysplastic syndrome, refractory immune thrombocytopenic purpura, atopic dermatitis, Behçet's syndrome
Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.
1.5 to 2.5 mg/kg orally once daily; typical adult dose 50-150 mg/day orally. Intravenous dose is 3-5 mg/kg/day as a slow infusion over 30-60 minutes.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life of azathioprine is approximately 2–5 hours; its active metabolite 6-mercaptopurine has a half-life of 1–2 hours, but 6-thioguanine nucleotides accumulate in red blood cells with a half-life of several days, correlating with myelosuppression.
Ivermectin is metabolized primarily by CYP3A4 to hydroxylated and demethylated metabolites. Phase II glucuronidation may occur. No active metabolites are identified.
Azathioprine is metabolized by xanthine oxidase (XO) and thiopurine methyltransferase (TPMT) to active (6-mercaptopurine) and inactive metabolites. 6-Mercaptopurine is further metabolized by XO to 6-thiouric acid and by TPMT to 6-methylmercaptopurine. Genetic deficiency of TPMT increases risk of toxicity.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; the remaining 10% is metabolized.
Renal (approximately 2% as unchanged drug, 30% as 6-thiouric acid and other metabolites); biliary/fecal (minor, <10% as metabolites).
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Approximately 30% bound, primarily to albumin.
Volume of distribution is 0.5 L/kg, indicating distribution primarily into extracellular fluid.
0.8–1.0 L/kg, indicating distribution into total body water; extensive distribution into tissues including liver and erythrocytes.
Oral bioavailability is 40–50% due to first-pass metabolism; intramuscular bioavailability is 80%.
Oral bioavailability of azathioprine is 60–80% (mean 70%) with interindividual variability; absorption may be reduced by food.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: not recommended.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: administer 75% of normal dose. GFR <10 m L/min: administer 50% of normal dose. Hemodialysis: administer 50% of normal dose after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: contraindicated or use with extreme caution; reduce dose by at least 50%.
Not approved for use in pediatric patients.
1.5 to 2.5 mg/kg orally once daily; maximum 150 mg/day. For inflammatory bowel disease: 2-3 mg/kg/day. Intravenous: 3-5 mg/kg/day as a slow infusion.
No specific dose adjustment; monitor for increased sensitivity and renal function.
Initiate at lower end of dosing range (1.5 mg/kg/day) due to potential for decreased renal and hepatic function; monitor renal function and hematologic parameters closely.
This drug should be used primarily for treatment of progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of disease (e.g., oral thrush, vaginal candidiasis).
Malignancy: Patients receiving immunosuppressive therapy including azathioprine have an increased risk of developing lymphoma and other malignancies, particularly skin cancers. The risk is related to the duration and intensity of immunosuppression. Hematologic toxicity: Severe leukopenia, thrombocytopenia, and anemia, which may be dose-related, can occur. Regular monitoring of blood counts is required. Hepatotoxicity: Hepatotoxicity, including fatal liver injury, has been reported, particularly at high doses.
Monitor renal function closely; may cause dose-dependent nephrotoxicity. Premedicate for infusion reactions (fever, chills, rigors). Monitor electrolytes (hypokalemia, hypomagnesemia). Risk of cardiotoxicity with rapid infusion. Use caution in patients with renal impairment; dose adjustment required.
Hematologic monitoring: regular CBCs; Increased risk of infection; Hepatotoxicity; Pancreatitis; Carcinogenicity (lymphoma, skin cancer); TPMT deficiency increases myelotoxicity; Vaccination (live vaccines contraindicated); Renal and hepatic impairment; Drug interactions: allopurinol (reduce dose by 75%), ACE inhibitors (anemia), warfarin (anticoagulant effect decreased).
Hypersensitivity to amphotericin B or any component of the formulation, unless the benefit outweighs the risk.
Hypersensitivity to azathioprine or 6-mercaptopurine; Pregnancy (unless benefit outweighs risk) - Category D; Lactation; Patients with TPMT deficiency (increased risk of severe myelotoxicity); Severely depressed bone marrow function; Active infections; Concurrent use of live vaccines; Pre-existing malignancy (except in organ transplantation context).
Avoid grapefruit and grapefruit juice as they may increase fingolimod concentrations. No specific dietary restrictions, but maintain adequate hydration.
No known significant food interactions. Avoid grapefruit juice? (No interaction reported). Maintain consistent diet; no specific restrictions. Limit alcohol due to hepatotoxicity risk.
Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, premature closure of ductus arteriosus, and neonatal renal impairment.
Azathioprine is pregnancy category D. First trimester: increased risk of congenital anomalies including ventricular septal defects, limb defects, and esophageal atresia. Second and third trimesters: risk of intrauterine growth restriction, preterm birth, and neonatal immunosuppression (leukopenia, thrombocytopenia). Use only if benefit outweighs risk.
Contraindicated. Excreted in human milk; M/P ratio not determined. Potential for serious adverse reactions in breastfed infants.
Azathioprine is excreted into breast milk in low concentrations. M/P ratio is approximately 0.7. Nursing infants of mothers on azathioprine have not shown adverse effects; however, theoretical risk of immunosuppression exists. Caution is advised; monitor infant for increased infections.
Increased renal clearance in pregnancy may require dose increments of 30-50% to maintain therapeutic levels; monitor serum lithium concentrations and adjust dose to therapeutic range (0.6-1.2 m Eq/L).
Pharmacokinetic changes in pregnancy include increased clearance and decreased absorption. Dose may need adjustment to maintain therapeutic efficacy. Close monitoring of disease activity and drug levels (6-thioguanine nucleotide levels) is recommended. No standard dose adjustment; individualization required.
ABLYSINOL (fingolimod) is a sphingosine-1-phosphate receptor modulator used for relapsing forms of multiple sclerosis. First-dose monitoring for bradycardia (6 hours) is mandatory; consider pre-treatment ECG. Avoid live vaccines during and for 2 months after therapy. Monitor for macular edema (ophthalmologic exam at baseline and 3-4 months). Lymphopenia is expected; check CBC before initiation and periodically. Drug interactions: QTc-prolonging agents, immunosuppressants, beta-blockers, calcium channel blockers. Do not use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias.
Monitor CBC and LFTs weekly for first month, then biweekly for 2 months, then monthly. TPMT genotype testing before initiation. Avoid concurrent allopurinol unless dose reduced to 25% of original. Use with caution in renal impairment. May cause hepatotoxicity, pancreatitis, or lymphoproliferative disorders.
Stay hydrated and avoid grapefruit juice; it may increase drug levels.,Report any vision changes, slow heartbeat, or dizziness immediately.,Avoid pregnancy; use effective contraception during and for 2 months after stopping.,Do not receive live vaccinations during treatment.,Take exactly as prescribed; do not skip doses or stop suddenly.
Take exactly as prescribed; do not double dose if missed.,Avoid live vaccines during treatment and for 3 months after stopping.,Report any signs of infection, unexplained bruising/bleeding, or jaundice immediately.,Limit sun exposure and use sunscreen due to increased skin cancer risk.,Do not take allopurinol or other new medications without consulting doctor.,Maintain adequate hydration to reduce risk of hepatotoxicity.,Regular blood tests are required to monitor for side effects.
No interactions on record
"Azathioprine may reduce the therapeutic efficacy and cardiotoxic effects of digitoxin by accelerating its metabolism through induction of cytochrome P450 enzymes, particularly CYP3A4. This interaction can lead to decreased digitoxin serum concentrations, potentially resulting in loss of heart rate control in patients with atrial fibrillation or heart failure. Conversely, the cardiotoxic risk of digitoxin is diminished, but the therapeutic goal may be compromised."
"Azathioprine and fingolimod both suppress lymphocyte function, leading to additive or synergistic immunosuppression. This combination increases the risk of severe infections, including opportunistic infections, due to profound immune system suppression. Clinically, patients may present with prolonged lymphopenia, increased susceptibility to infections, and potential reactivation of latent viruses such as JC virus (causing progressive multifocal leukoencephalopathy) or cytomegalovirus."
"Azathioprine, an immunosuppressant that acts as a prodrug for 6-mercaptopurine, can increase the myelosuppressive effects of benazepril, an ACE inhibitor. This interaction is likely due to additive bone marrow suppression, leading to an elevated risk of leukopenia, anemia, and thrombocytopenia, especially in patients with renal impairment or concomitant use of other myelosuppressive agents."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABLYSINOL vs AZATHIOPRINE, answered by our medical review team.
ABLYSINOL is a Calcineurin inhibitor that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.. AZATHIOPRINE is a Immunosuppressant that works by Azathioprine is a purine analog that inhibits purine nucleotide synthesis, thereby suppressing DNA replication and cell proliferation. It is converted to 6-mercaptopurine, which acts as a purine antagonist, inhibiting de novo purine synthesis and interfering with RNA and DNA synthesis, particularly in rapidly dividing cells such as T-lymphocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABLYSINOL and AZATHIOPRINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABLYSINOL is: Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.. The standard adult dose of AZATHIOPRINE is: 1.5 to 2.5 mg/kg orally once daily; typical adult dose 50-150 mg/day orally. Intravenous dose is 3-5 mg/kg/day as a slow infusion over 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABLYSINOL and AZATHIOPRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABLYSINOL is classified as Category C. Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, p. AZATHIOPRINE is classified as Category D/X. Azathioprine is pregnancy category D. First trimester: increased risk of congenital anomalies including ventricular septal defects, limb defects, and esophageal atresia. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.